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TZT-1027 is a novel anticancer agent that inhibits microtubule polymerisation and manifests potent antitumour activity in preclinical
models. We have examined the effect of TZT-1027 on cell cycle progression as well as the anticancer activity of this drug both in vitro
and in vivo. With the use of tsFT210 cells, which express a temperature-sensitive mutant of Cdc2, we found that TZT-1027 arrests
cell cycle progression in mitosis, the phase of the cell cycle most sensitive to radiation. A clonogenic assay indeed revealed that TZT-
1027 increased the sensitivity of H460 cells to g-radiation, with a dose enhancement factor of 1.2. Furthermore, TZT-1027 increased
the radiosensitivity of H460 and A549 cells in nude mice, as revealed by a marked delay in tumour growth and an enhancement
factor of 3.0 and 2.2, respectively. TZT-1027 also potentiated the induction of apoptosis in H460 cells by radiation both in vitro and in
vivo. Histological evaluation of H460 tumours revealed that TZT-1027 induced morphological damage to the vascular endothelium
followed by extensive central tumour necrosis. Our results thus suggest that TZT-1027 enhances the antitumour effect of ionising
radiation, and that this action is attributable in part to potentiation of apoptosis induction and to an antivascular effect. Combined
treatment with TZT-1027 and radiation therefore warrants investigation in clinical trials as a potential anticancer strategy.
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The combination of modalities of cancer treatment offers
improvements in the survival of cancer patients compared
with individual therapeutic approaches. Such therapeutic benefit
has been achieved with combinations of chemo- and radiotherapy
in a variety of cancers. The cytotoxicity of most chemotherapeutic
agents as well as that of radiation is highly dependent on the
phase of the cell cycle. Although various types of anticancer
drugs are able to arrest cells at specific cell cycle checkpoints, the
ability of antimicrotubule agents to block cell cycle progression
in G2-M phase is the biological basis for combination of
these agents with radiation (Pawlik and Keyomarsi, 2004).
Microtubule-interfering agents have been shown to increase the
radiosensitivity of tumour cells in preclinical and clinical studies
(Liebmann et al, 1994; Choy et al, 1995; Edelstein et al, 1996; Vokes
et al, 1996; Kim et al, 2001, 2003; Hofstetter et al, 2005; Simoens
et al, 2006).
TZT-1027 (Soblidotin), a novel microtubule-interfering agent
synthesised from dolastatin 10 (Figure 1), exhibits greater
antitumour activities and a reduced toxicity compared with its
parent compound (Miyazaki et al, 1995). TZT-1027 inhibits
microtubule assembly by binding to tubulin (Kobayashi et al,
1997; Natsume et al, 2000). In vitro, it inhibits the growth of
various human cancer cells at low concentrations (Watanabe et al,
2000). In vivo, TZT-1027 also manifests a broad spectrum of
activity against various murine tumours as well as human tumour
xenografts, without inducing a pronounced reduction in body
weight (Kobayashi et al, 1997; Watanabe et al, 2000, 2006a;
Natsume et al, 2003, 2006). Furthermore, the drug exhibited a
potent antivascular effect on existing vasculature in an advanced-
stage tumour model (Otani et al, 2000). TZT-1027 is currently
undergoing clinical evaluation, with a reduction in tumour size
and disease stabilisation having been observed in a subset of
patients (Schoffski et al, 2004; de Jonge et al, 2005; Greystoke et al,
2006; Tamura et al, 2007).
Despite its demonstrated efficacy against solid tumours, the
effects of TZT-1027 in combination with radiation have not been
examined. As an initial step in determining the antitumour activity
of TZT-1027 in combination with radiation, we investigated the
effect of this agent on cell cycle progression in synchronised
tsFT210 cells (Osada et al, 1997), which harbour a temperature-
sensitive mutant of Cdc2. We found that TZT-1027 induces arrest
of cells in mitosis, the phase of the cell cycle most sensitive to
radiation. We then studied the radiosensitising properties of TZT-
1027 in vitro and in vivo with a human lung cancer model and
elucidated the mechanism of radiosensitisation by this agent.
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sMATERIALS AND METHODS
Cell lines and reagents
tsFT210 mouse mammary carcinoma cells, which express a
temperature-sensitive mutant of Cdc2, were kindly provided by
H Kakeya (Antibiotics Laboratory, Discovery Research Institute,
RIKEN, Saitama, Japan) and were maintained under a humidified
atmosphere of 5% CO2 in air at 32.01C in RPMI 1640 (Sigma, St
Louis, MO, USA) supplemented with 10% foetal bovine serum and
1% penicillin-streptomycin. H460 human lung large cell carcinoma
and A549 human lung adenocarcinoma cells were obtained from
American Type Culture Collection (Manassas, VA, USA) and were
maintained as for tsFT210 cells with the exception that the culture
temperature was 371C. TZT-1027 (Figure 1) was provided by
Daiichi Pharmaceutical Co. Ltd (Tokyo, Japan). Nocodazole and
roscovitine were obtained from Sigma.
Cell cycle analysis
Cells were harvested, washed with phosphate-buffered saline
(PBS), fixed with 70% methanol, washed again with PBS, and
stained with propidium iodide (0.05mgml
 1) in a solution
containing 0.1% Triton X-100, 0.1mM EDTA, and RNase A
(0.05mgml
 1). The stained cells (B1 10
6) were then analysed
for DNA content with a flow cytometer (FACScalibur; Becton
Dickinson, San Jose, CA, USA).
Measurement of mitotic index and apoptotic cells
Cells were harvested, washed with PBS, fixed with methanol:acetic
acid (3:1, v/v), washed again with PBS, and stained with 40,6-
diamidino-2-phenylindole (DAPI) (0.5mgml
 1). The stained cells
(B1 10
6) were observed with a fluorescence microscope (IX71;
Olympus, Tokyo, Japan). To determine the proportion of mitotic
or apoptotic cells, we scored at least 300 cells in each of at least
three randomly selected microscopic fields for each of three slides
per sample. Cells with condensed chromosomes and no obvious
nuclear membrane were regarded as mitotic cells, and the mitotic
index was calculated as the percentage of mitotic cells among total
viable cells. Cells with fragmented and uniformly condensed nuclei
were regarded as apoptotic cells.
Clonogenic assay
Exponentially growing H460 cells in 25-cm
2 flasks were harvested
by exposure to trypsin and counted. They were diluted serially to
appropriate densities and plated in triplicate in 25-cm
2 flasks
containing 10ml of medium. The cells were treated with 1nM TZT-
1027 or vehicle (dimethyl sulfoxide, or DMSO; final concentration,
0.1%) for 24h and then exposed to various doses of g-radiation
with a
60Co irradiator at a rate of B0.82Gymin
 1 and at room
temperature. The cells were then washed with PBS, cultured in
drug-free medium for 10–14 days, fixed with methanol:acetic acid
(10:1, v/v), and stained with crystal violet. Colonies containing
450 cells were counted. The surviving fraction was calculated as:
(mean number of colonies)/(number of inoculated cells plating
efficiency). Plating efficiency was defined as the mean number of
colonies divided by the number of inoculated cells for nonirra-
diated controls. The surviving fraction for combined treatment
was corrected by that for TZT-1027 treatment alone. The dose
enhancement factor (DEF) was calculated as the dose (Gy) of
radiation that yielded a surviving fraction of 0.1 for vehicle-treated
cells divided by that for TZT-1027-treated cells (after correction
for drug toxicity).
In vivo antitumour activity of TZT-1027 with or without
radiation
All animal studies were performed in accordance with the
Recommendations for Handling of Laboratory Animals for
Biomedical Research, compiled by the Committee on Safety and
Ethical Handling Regulations for Laboratory Animal Experiments,
Kyoto University. The ethical guidelines followed meet the
requirements of the UKCCCR guidelines (Workman et al, 1998).
Tumour cells (2 10
6) were injected subcutaneously into the right
hind leg of 7-week-old female athymic nude mice. Tumour volume
was determined from caliper measurement of tumour length (L)
and width (W) according to the formula LW
2/2. Treatment was
initiated when tumours in each group achieved an average volume
of B200–250mm
3. Treatment groups consisted of control, TZT-
1027 alone, radiation alone, and the combination of TZT-1027 and
radiation. Each treatment group contained six to eight mice. TZT-
1027 was administered intravenously in a single dose of 0.5mgkg
 1
of body weight; mice in the control and radiation-alone groups
were injected with vehicle (physiological saline). Tumours in the leg
were exposed to 10Gy of g-radiation with a
60Co irradiator at a rate
of B0.32Gymin
 1 immediately after drug treatment. Growth
delay (GD) was calculated as the time for treated tumours to
achieve an average volume of 500mm
3 minus the time for control
tumours to reach 500mm
3. The enhancement factor was then
determined as: (GDcombination–GDTZT 1027)/(GDradiation).
TUNEL staining
Mice were killed 14 days after treatment initiation and the tumours
were removed and preserved in 10% paraformaldehyde. Apoptosis
in tumour sections was determined by the terminal deoxynucleo-
tidyl transferase-mediated dUTP-biotin nick-end labelling (TUNEL)
assay with the use of an apoptosis detection kit (Chemicon,
Temecula, CA, USA). The number of apoptotic cells was counted
in 10 separate microscopic fields ( 100) for three sections of each
tumour of each group.
Histological analysis
A single dose of TZT-1027 (2.0mgkg
 1) or vehicle (physiological
saline) was administered intravenously to mice when H460
tumours had achieved a volume of B400 to 600mm
3. Tumour
tissue was extirpated 4 or 24h after drug administration, and half
of the tissue was fixed in 10% buffered formalin, embedded in
paraffin, sectioned, and stained with hematoxylin-eosin. The other
half of the tumour tissue was fixed for 12–48h in zinc fixative
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Figure 1 Chemical structure of TZT-1027.
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s(BD Biosciences, San Jose, CA, USA), embedded in paraffin,
sectioned, and immunostained for CD31. Endogenous peroxidase
activity was blocked by incubation of the latter sections for 20min
with 0.3% H2O2 in methanol, and nonspecific sites were blocked
with antibody diluent (Dako Japan, Kyoto, Japan). Sections were
then incubated overnight at 41C with a 1:50 dilution of a rat
monoclonal antibody to mouse CD31 (BD Biosciences), washed
with PBS, and processed with a Histfine Simple Stain PO (M) kit
(Nichirei, Tokyo, Japan) for detection of immune complexes.
Sections were counterstained with Mayer’s hematoxylin, covered
with a coverslip with the use of a permanent mounting medium,
and examined with a light microscope (CX41; Olympus, Tokyo,
Japan).
Statistical analysis
Data are presented as means7s.d. or s.e. and were compared by
the unpaired Student’s t-test. A P value of o0.05 was considered
statistically significant.
RESULTS
Induction of cell cycle arrest at M phase but not at G1-S in
tsFT210 cells by TZT-1027
To examine the effect of TZT-1027 on cell cycle progression, we
performed flow cytometric analysis of tsFT210 cells, which express
a temperature-sensitive mutant of Cdc2. These mammary carci-
noma cells exhibit a normal cell cycle distribution when incubated
at the permissive temperature of 32.01C, but they arrest at G2
phase as a result of Cdc2 inactivation when incubated at the
nonpermissive temperature of 39.41C (Figure 2A and B). We
synchronised tsFT210 cells at G2 phase by incubation at 39.41C for
17h and then cultured them at 32.01C for 6h in the presence of
nocodazole (an inhibitor of microtubule polymerisation), TZT-
1027, or vehicle (DMSO). In the presence of vehicle alone, the
number of cells in G2 phase decreased markedly and there was a
corresponding increase in the number of cells in G1 phase,
indicative of re-entry of cells into the cell cycle (Figure 2C). In
contrast, treatment with nocodazole or TZT-1027 prevented the
cells from passing through G2-M phase (Figure 2D and E). Given
that flow cytometric analysis did not distinguish between cells in M
phase and those in G2 phase, we determined the mitotic index of
cells by DAPI staining and fluorescence microscopy. Most of the
cells released from temperature-induced arrest in the presence of
nocodazole manifested condensed chromosomes without a nuclear
membrane, yielding a mitotic index of 93%; most of the cells had
thus arrested in mitosis (Figure 2D). Most of the cells released
from temperature-induced arrest in the presence of TZT-1027
showed similar mitotic figures, yielding a mitotic index of 85%
(Figure 2E) and demonstrating that TZT-1027 also inhibits cell
cycle progression at mitosis.
We next examined whether TZT-1027 affects the G1-S transition.
We arrested tsFT210 cells at G2 phase by incubation at 39.41C,
released the cells into G1 phase by shifting to the permissive
temperature for 6h, and then incubated them for an additional 6h
in the presence of roscovitine (an inhibitor of CDK2 that prevents
cell cycle progression at G1 phase), TZT-1027, or vehicle (Figure 3).
The cells incubated with vehicle passed through G1 phase and
yielded a broad S-phase peak (Figure 3D), whereas those treated
with roscovitine did not pass through G1 phase (Figure 3E). In
contrast, TZT-1027 had no effect on passage of the synchronised
tsFT210 cells through the G1-S transition (Figure 3F). Together,
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Figure 2 Inhibition of tsFT210 cell cycle progression through G2-M by TZT-1027. Cells were cultured at the permissive temperature of 32.01C( A) and
then incubated for 17h at the nonpermissive temperature of 39.41C( B). They were subsequently released from G2 arrest by incubation at 32.01C for 6h in
the presence of DMSO (C), 1mM nocodazole (D), or 2nM TZT-1027 (E). At each stage of the protocol, cells were analysed for DNA content by staining
with propidium iodide and flow cytometry. The 2N and 4N peaks indicate cells in G0-G1 and G2-M phases of the cell cycle, respectively. The cells were also
stained with DAPI and examined by fluorescence microscopy after treatment with DMSO, nocodazole, or TZT-1027 (lower panels), and the mitotic index
(MI) was determined; scale bar, 20mm. Data are representative of at least three independent experiments.
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sthese results indicate that the effect of TZT-1027 on cell cycle
progression is specific to M phase.
Induction of cell cycle arrest at M phase in asynchronous
H460 cells by TZT-1027
We next examined whether TZT-1027 induced mitotic arrest in
asynchronous H460 human non-small cell lung cancer cells. Flow
cytometric analysis revealed that treatment of H460 cells with TZT-
1027 for 24h induced a threefold increase in the proportion of cells
with a DNA content of 4N compared with that apparent for
vehicle-treated cells (29.1 vs 8.7%) (Figure 4A and B). Further-
more, DAPI staining revealed that TZT-1027 induced a significant
increase in the mitotic index of H460 cells compared with that for
the control cells (23.3 vs 4.6%) (Figure 4C and D), indicating that
most of the TZT-1027-treated cells with a DNA content of 4N were
arrested in M phase rather than in G2 phase. These observations
thus showed that TZT-1027 also induced mitotic arrest in
asynchronous H460 cells.
Radiosensitisation of H460 cells by TZT-1027 in vitro
Cells in M phase are more sensitive to radiation than are those in
other phases of the cell cycle. Given that exposure of H460 cells to
TZT-1027-induced mitotic arrest, we next examined whether this
agent might sensitise H460 cells to g-radiation with the use of a
clonogenic assay. H460 cells were incubated for 24h with 1nM
TZT-1027 or vehicle (DMSO) and then exposed to various doses
(0, 2, 4, or 6Gy) of g-radiation. The cells were then allowed to form
colonies in drug-free medium for 10–14 days. Survival curves
revealed that TZT-1027 increased the radiosensitivity of H460 cells,
with a DEF of 1.2 (Figure 5A).
To determine whether radiosensitisation by TZT-1027 was
reflected by an increase in the proportion of apoptotic cells,
we exposed H460 cells to 1nM TZT-1027 or vehicle for 24h,
treated the cells with various doses (0, 2, 4, or 6Gy) of radiation,
and then incubated them in drug-free medium for an additional
24h before quantification of apoptosis. Combined treatment with
TZT-1027 and 4 or 6Gy of radiation resulted in a significant
increase in the number of apoptotic cells compared with the sum
of the values for treatment with drug alone or radiation alone
(Figure 5B). TZT-1027 thus promoted radiation-induced apoptosis
in H460 cells.
Radiosensitisation of H460 cells and A549 cells by
TZT-1027 in vivo
To determine whether the TZT-1027-induced increase in the
radiosensitivity of tumour cells observed in vitro might also be
apparent in vivo, we injected H460 cells or A549 human lung
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Figure 3 Lack of effect of TZT-1027 on tsFT210 cell cycle progression
through G1-S. Exponentially growing tsFT210 cells (A) were arrested in G2
phase by incubation for 17h at 39.41C( B). The cells were incubated at
32.01C first for 6h to allow progression to G1 phase (C) and then for an
additional 6h in the presence of DMSO (D), 50mM roscovitine (E), or 2nM
TZT-1027 (F). At each stage of the protocol, cells were analysed for DNA
content by flow cytometry. Data are representative of at least three
independent experiments.
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Figure 4 Induction of cell cycle arrest at M phase in H460 cells by TZT-1027. H460 cells were incubated in the presence of 1nM TZT-1027 or vehicle
(DMSO) for 24h, after which DNA content was measured by flow cytometry (A) and the fraction of cells in G2-M phase was determined (B). The cells
were also stained with DAPI and examined by fluorescence microscopy (C) and the mitotic index was determined (D). Data in (A) through (C) are
representative of at least three independent experiments; data in (D) are means7s.d. of values from three independent experiments. Scale bar in (C),
20mm.
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sadenocarcinoma cells into nude mice in order to elicit the
formation of solid tumours. The mice were then treated with
TZT-1027, radiation, or both modalities. Treatment with TZT-1027
alone (single dose of 0.5mgkg
 1) or with radiation alone (single
dose of 10Gy) resulted in relatively small inhibitory effects on
tumour growth, whereas combined treatment with both TZT-1027
and radiation exerted a markedly greater inhibitory effect (Figure
6A and B). The tumour GDs induced by treatment with TZT-1027
alone, radiation alone, or both TZT-1027 and radiation were 1.0,
2.6, and 8.8 days, respectively, for H460 cells and 1.4, 4.9, and 12.4
days, respectively, for A549 cells (Table 1). The enhancement
factor for the effect of TZT-1027 on the efficacy of radiation was
3.0 for H460 cells and 2.2 for A549 cells, revealing the effect to be
greater than additive. No pronounced tissue damage or toxicities
such as diarrhoea or weight loss of 410% were observed in mice
in any of the four treatment groups (Table 2).
We examined the effects of the treatment protocols on apoptosis
in H460 tumours by TUNEL staining of tumour sections.
Quantification of the number of apoptotic cells revealed that the
combined treatment with radiation and TZT-1027 induced a
significant increase in this parameter compared with treatment
with radiation or TZT-1027 alone (Figure 6C).
Histological appearance of H460 tumours after
administration of TZT-1027
Finally, we examined whether an effect of TZT-1027 on tumour
vasculature might contribute to the antitumour activity of this
drug in vivo. Mice harbouring H460 tumours were injected with
TZT-1027, and the tumours were excised 4 or 24h thereafter and
examined by hematoxylin-eosin staining (Figure 7A–C) or by
immunostaining for the endothelial cell marker CD31 (Figure 7D
and E). Tumour capillaries appeared congested, with thrombus
formation, and showed a loss of endothelial cells 4h after
administration of TZT-1027 (Figure 7B and E), whereas vessels
within viable areas of control tumours were generally not
congested and showed an intact normal endothelium (Figure 7A
and D). The effects of TZT-1027 on the tumour vasculature
appeared selective, given that neither loss of CD31 staining nor
vessel congestion was apparent in the vasculature of surrounding
normal tissue after drug treatment (Figure 7E). Extensive necrosis
was apparent at the tumour core, with a characteristic thin rim of
viable tumour cells remaining at the periphery, 24h after TZT-
1027 administration (Figure 7C). These results were thus indicative
of a characteristic antivascular effect of TZT-1027 in the H460
tumour model.
DISCUSSION
TZT-1027 is a novel antitumour agent that inhibits microtubule
polymerisation and exhibits potent antitumour activity in
preclinical models (Miyazaki et al, 1995; Kobayashi et al, 1997;
Natsume et al, 2000, 2003, 2006; Otani et al, 2000; Watanabe et al,
2000, 2006a). We investigated the effect of TZT-1027 on cell cycle
progression with the use of tsFT210 cells, which can be
synchronised in G2 phase by incubation at 39.41C and consequent
inactivation of Cdc2 (Osada et al, 1997; Tamura et al, 1999). The
use of these cells allows cell synchronisation without the need for
agents that prevent DNA synthesis (such as hydroxyurea or
thymidine) or that inhibit formation of the mitotic spindle (such
as nocodazole). Although such agents halt cell cycle progression
in specific phases of the cycle, they are also toxic and kill a
proportion of the treated cells. The tsFT210 cell system is thus
suited to sensitive analysis of the effects of new compounds on cell
cycle progression without loss of cell viability. We have now shown
that tsFT210 cells released from G2 arrest by incubation at 32.01C
failed to pass through M phase in the presence of TZT-1027.
Although previous flow cytometric analysis of exponentially
growing tumour cells revealed that TZT-1027 induced a marked
increase in the proportion of cells in G2-M (Watanabe et al, 2000),
it was uncertain whether the drug arrested cell cycle progression in
G2 or in mitosis. Our morphological data now indicate that, similar
to the effect of nocodazole, TZT-1027 arrested tsFT210 cells in M
phase rather than in G2, consistent with the mode of action of this
new compound. Given that microtubules contribute to various
cellular functions in addition to cell division, including intra-
cellular transport and signal transduction (Mollinedo and Gajate,
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Figure 5 Sensitisation of H460 cells to g-radiation by TZT-1027 in vitro.( A) Clonogenic assay. Cells were incubated with 1nM TZT-1027 or vehicle
(DMSO) for 24h, exposed to the indicated doses of g-radiation, and then incubated in drug-free medium for 10–14 days for determination of colony-
forming ability. Survival curves were generated after correction of colony formation observed for combined treatment with ionising radiation (IR) and TZT-
1027 by that apparent for treatment with TZT-1027 alone. (B) Assay of apoptosis. Cells were incubated with 1nM TZT-1027 or vehicle (DMSO) for 24h,
exposed to various doses (0, 2, 4, or 6Gy) of g-radiation, and then incubated for 24h in drug-free medium. Cells were then fixed and stained with DAPI for
determination of the proportion of apoptotic cells by fluorescence microscopy. Data in (A) and (B) are means7s.d. of values from three independent
experiments. P values in (B) are for comparison of the value for combined treatment with TZT-1027 and radiation vs the sum of the corresponding values
for each treatment alone, after correction of all data by the control (DMSO) value.
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s2003), TZT-1027 might also be expected to affect tumour cells in
interphase. With the use of synchronised tsFT210 cells, however,
we found that TZT-1027 had no effect on progression of cells
through the G1–S transition of the cell cycle. The effect of TZT-
1027 on cell cycle progression thus appears to be specific to M
phase.
Given that cells are most sensitive to radiation during mitosis
(Sinclair and Morton, 1966; Sinclair, 1968; Pawlik and Keyomarsi,
2004), we next investigated the possible interaction between TZT-
1027 and ionising radiation in human lung cancer cell lines. We
found that TZT-1027 increased the sensitivity of H460 cells to g-
radiation in vitro. The proportion of H460 cells in mitotic phase
at the time of irradiation was increased by TZT-1027 treatment,
consistent with the notion that this effect contributes to the
observed radiosensitisation induced by this drug. TZT-1027 was
previously shown to induce apoptosis in several tumour cell lines
(Watanabe et al, 2000). Although the relation between apoptosis
and radiosensitivity is controversial (Lawrence et al, 2001; Pawlik
and Keyomarsi, 2004), we showed that treatment of H460 cells with
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Figure 6 Sensitisation of H460 and A549 cells to g-radiation by TZT-1027 in vivo.( A and B) Evaluation of tumour growth. Nude mice with H460 (A)o r
A549 (B) tumour xenografts (B200 to 250mm
3) were treated with a single intravenous dose of TZT-1027 (0.5mgkg
 1), a single dose of g-radiation
(10Gy), or neither (control) or both modalities, and tumour volume was determined at the indicated times thereafter. Data are means7s.e. for six to eight
mice per group. (C) Quantification of apoptotic cells in H460 tumour sections by TUNEL staining 14 days after the initiation of treatment as in (A). Data are
means7s.d. *Po0.05 vs mice treated with TZT-1027 alone or radiation alone.
Table 1 Tumour growth delay value
H460 A549
Treatment Days
a GD
b Days GD
Control 4.5 5.5
TZT-1027 alone 5.5 1 6.9 1.4
Radiation alone 7.1 2.6 10.4 4.9
TZT-1027 + Radiation 13.3 8.8 17.9 12.4
Enhancement factor 3 2.2
aDays, the period needed for the sizes of xenografts in each group to reach 500mm
3;
bGD, the additional periods needed for the sizes of xenografts in each group to reach
500mm
3 in addition to the period needed for controls to reach 500mm
3.
Table 2 Body weight loss
% of B.W.L
a
H460 A549
Control 3.6 1.2
TZT-1027 alone 9.9 5.2
Radiation alone 9.7 5.5
TZT-1027+Radiation 8.7 9.9
a% of B.W.L, relative body weight loss 7 days after the initiation of the treatment.
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proportion of apoptotic cells compared with that apparent with
radiation alone. These results thus suggested that potentiation of
apoptosis contributed to radiosensitisation by TZT-1027.
Combined treatment with radiation and a single administration
of TZT-1027 also inhibited the growth of tumours formed by H460
or A549 cells in vivo to a greater extent than did either treatment
alone. Tumour microenvironmental factors, such as the vascular
supply, are important determinants of sensitivity to radiation
therapy in vivo. The ability of microtubule-targeting agents to
induce a rapid shutdown of the existing tumour vasculature has
been recognised by their designation as vascular-targeting agents
(VTAs) (Jordan and Wilson, 2004). Treatment with VTAs such
as ZD6126 and combretastatin A-4-P typically results in the
destruction of large areas of a tumour, with surviving cells
remaining only at the tumour periphery (Dark et al, 1997; Blakey
et al, 2002). These peripheral viable tumour cells presumably
derive their nutritional support from nearby normal blood vessels
that are not responsive to VTA treatment (Li et al, 1998; Siemann
and Rojiani, 2002). Such support together with a rapid upregula-
tion of angiogenic factors such as vascular endothelial growth
factor may directly facilitate the growth and expansion of the
remaining tumour cells (Wachsberger et al, 2003; Thorpe, 2004).
Given that these residual tumour cells are likely well oxygenated
(Wachsberger et al, 2003), they are an ideal target for radiation
therapy. Several studies have recently shown that treatment with
VTAs enhances the therapeutic effect of radiotherapy (Li et al,
1998; Siemann and Rojiani, 2002, 2005; Horsman and Murata,
2003; Masunaga et al, 2004), consistent with the idea that the
components of such combination therapy act in a complementary
manner, with VTAs attacking the poorly oxygenated cell popula-
tion in the central region of tumours and radiation killing the
well-oxygenated proliferating cells at the tumour periphery
(Li et al, 1998; Siemann and Rojiani, 2002; Wachsberger et al,
2003). TZT-1027 was previously shown to increase vascular
permeability and to induce a decrease in tumour blood flow
followed by a marked increase in tissue necrosis in the central
region of tumour xenografts (Otani et al, 2000; Watanabe et al,
2006b). We have now shown that TZT-1027 treatment resulted in
congestion and occlusion of tumour blood vessels followed by
extensive necrosis of the tumour core, with only a thin rim of
viable tumour cells remaining, in the H460 tumour model,
suggesting that TZT-1027 acts as a VTA. The action of TZT-1027
as a VTA might thus contribute to the radiosensitising effect
observed in vivo in the present study.
The clinical use of microtubule-interfering agents such as
taxanes in combination with radiation has been successful in
improving local tumour control. However, taxanes are often of
limited efficacy because of the development of cellular resistance
such as that mediated by P-glycoprotein-dependent drug efflux
(Goodin et al, 2004). The action of TZT-1027 has been suggested to
be less affected by multidrug resistance factors, including over-
expression of P-glycoprotein, than that of other tubulin inhibitors
(Watanabe et al, 2006a), suggesting that TZT-1027 may be effective
in the treatment of taxane-refractory tumours. Further investiga-
tions are thus warranted to examine the combined effects of
TZT-1027 and ionising radiation on drug-resistant tumour cells.
Whether TZT-1027 enhances the tumour response to clinically
relevant fractionated doses of radiation such as 2Gy per fraction
also warrants further study.
In conclusion, we have found that the inhibitory effect of
TZT-1027 on cell cycle progression is highly specific to M phase.
Moreover, TZT-1027 enhanced the effects of radiation on human
cancer cells both in vitro and in animal models in vivo. These
preclinical results provide a rationale for future clinical investiga-
tions of the therapeutic efficacy of TZT-1027 in combination with
radiotherapy.
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Figure 7 Histological analysis of H460 tumours after treatment with TZT-1027. Mice bearing H460 tumour xenografts were treated with a single dose of
TZT-1027 (2.0mgkg
 1), and the tumours were excised at various times thereafter and either stained with hematoxylin-eosin (A–C) or immunostained for
CD31 (D and E). (A and D) Control sections of an untreated tumour showing normal capillaries with an intact endothelium and viable tumour cells. (B and
E) Sections of a tumour removed 4h after administration of TZT-1027. Vascular congestion, with pink deposits of fibrin, and loss of endothelial cells as well
as diffuse tumour cell degeneration are apparent in (b). Dark immunostaining of intact endothelium (arrows) is apparent in surrounding normal connective
tissue, whereas little staining of endothelial cells was observed in the core (C) of the tumour (E). (C) Section of a tumour removed 24h after TZT-1027
administration, showing extensive central necrosis (N) and a rim of viable cells (V). Scale bars: 50mm( A and B), 100mm( C), and 200mm( D and E).
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